| Primary information |
|---|
| sequence ID | Seq_5626 |
| Peptide sequence | NGFKSHALQLNNRQ |
| CancerPDF_ID | CancerPDF_ID36, CancerPDF_ID905, CancerPDF_ID1051, CancerPDF_ID1921, CancerPDF_ID9612, CancerPDF_ID9934, CancerPDF_ID11945, CancerPDF_ID12711, |
| PMID | 16896061,19795908,16395409,21136997,21533267,21124649,26992070,27058005 |
| Protein Name | Complement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C4-B,Complement C4-A,Complement C4-A,Complement C4-B,Complement C4 |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4A_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4A_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 1626.85,542.95,1626.85,1625.83864,542.95,NA,1625.8386,1626.912 |
| Charge | 1,3,1,1,3,NA,NA,NA |
| Mass (in Da) | 1626.84,NA,NA,NA,NA,NA,1626.850864,NA |
| fdr | NA,NA,NA,NA,NA,1626.8,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC-ESI-MS/MS,LC-MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,Multiple Reaction Monitoring,NA,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,1.49,NA,FDR 1 %,NA |
| CancerPDF_ID | CancerPDF_ID36, CancerPDF_ID905, CancerPDF_ID1051, CancerPDF_ID1921, CancerPDF_ID9612, CancerPDF_ID9934, CancerPDF_ID11945, CancerPDF_ID12711, |
| p-Value | 1.00E-05,NA,4.28E-10,NA,NA,6.69E-12,NA,"less than 0.001,0.058,less than 0.05" |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,NA,SEQUEST and Maxquant,Proteome Discoverer |
| Length | 14,14,14,14,14,14,14,14 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Lung adenocarcinoma,Breast cancer,Melanoma,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4),NCBI Protein Database,SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,9 BC and 9 control,8 cancer samples and 4 healthy samples," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively",NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs control,"Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples.","Upregulated with the fold change of 0.56 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.80, Upregulated in BC vs healthy with 0.754 fold change" |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,MRM-based validation of 19 candidates,NA,na,NA |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |